Mark Richard Ashton
Directeur/Membre du Conseil chez Vaxxas Pty Ltd.
Profil
Mark Richard Ashton currently works at UniQuest Pty Ltd., as Director-Intellectual Property Commercialization from 2015 and Vaxxas Pty Ltd., as Director from 2013.
Dr. Ashton also formerly worked at Helmedix Pty Ltd., as Director, Dimerix Bioscience Pty Ltd., as Independent Non-Executive Director, and Evotec SE, as Executive Vice President-Business Development.
Postes actifs de Mark Richard Ashton
| Sociétés | Poste | Début |
|---|---|---|
Vaxxas Pty Ltd.
 Vaxxas Pty Ltd. Medical SpecialtiesHealth Technology Vaxxas Pty Ltd. develops and commercializes needle-free vaccine delivery system solutions. Its flagship products, Nanopatch, consists of an array of thousands of vaccine coated microprojections that perforate into the outer layers of the skin when applied with an applicator device. The tips of Nanopatch's microprojections are coated with a vaccine material and release this material directly to the large numbers of key immune cells immediately below the skin surface. The company was founded by Mark Kendall in August 2011 and is headquartered in Sydney, Australia. | Directeur/Membre du Conseil | - |
UniQuest Pty Ltd.
 UniQuest Pty Ltd. Miscellaneous Commercial ServicesCommercial Services UniQuest Pty Ltd. operates as a commercialization company of The University of Queensland. It specializes in industry-university collaborations, global technology transfer, and provide access to UQ's world-class expertise, intellectual property, and facilities. The company was founded in July 1984 and is headquartered in Brisbane, Australia. | Corporate Officer/Principal | 01/01/2010 |
Anciens postes connus de Mark Richard Ashton
| Sociétés | Poste | Fin |
|---|---|---|
Dimerix Bioscience Pty Ltd.
 Dimerix Bioscience Pty Ltd. Medical DistributorsDistribution Services Dimerix Bioscience Pty Ltd. engages in the development and commercialization of drug therapies and drug discovery tools. It deals with clinical research organizations to progress its programs through clinical studies. It focuses on the clinical development of its therapeutic product DMX200 which is targeted to treat patients with chronic kidney disease. The company was founded by James Howard Williams on December 16, 2004 and is headquartered in Melbourne, Australia. | Directeur/Membre du Conseil | - |
Helmedix Pty Ltd.
 Helmedix Pty Ltd. Pharmaceuticals: MajorHealth Technology Helmedix Pty Ltd. develops novel therapies for autoimmune diseases. It uses peptides derived from helminthes parasite to treat rheumatoid arthritis, colitis, psoriasis and multiple sclerosis. The company was founded by Andrew Hutchinson on December 1, 2012 and is headquartered in Melbourne, Australia. | Directeur/Membre du Conseil | - |
| EVOTEC SE | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| EVOTEC SE | Health Technology |
| Entreprise privées | 4 |
|---|---|
Vaxxas Pty Ltd.
Vaxxas Pty Ltd. Medical SpecialtiesHealth Technology Vaxxas Pty Ltd. develops and commercializes needle-free vaccine delivery system solutions. Its flagship products, Nanopatch, consists of an array of thousands of vaccine coated microprojections that perforate into the outer layers of the skin when applied with an applicator device. The tips of Nanopatch's microprojections are coated with a vaccine material and release this material directly to the large numbers of key immune cells immediately below the skin surface. The company was founded by Mark Kendall in August 2011 and is headquartered in Sydney, Australia. | Health Technology |
UniQuest Pty Ltd.
UniQuest Pty Ltd. Miscellaneous Commercial ServicesCommercial Services UniQuest Pty Ltd. operates as a commercialization company of The University of Queensland. It specializes in industry-university collaborations, global technology transfer, and provide access to UQ's world-class expertise, intellectual property, and facilities. The company was founded in July 1984 and is headquartered in Brisbane, Australia. | Commercial Services |
Dimerix Bioscience Pty Ltd.
Dimerix Bioscience Pty Ltd. Medical DistributorsDistribution Services Dimerix Bioscience Pty Ltd. engages in the development and commercialization of drug therapies and drug discovery tools. It deals with clinical research organizations to progress its programs through clinical studies. It focuses on the clinical development of its therapeutic product DMX200 which is targeted to treat patients with chronic kidney disease. The company was founded by James Howard Williams on December 16, 2004 and is headquartered in Melbourne, Australia. | Distribution Services |
Helmedix Pty Ltd.
Helmedix Pty Ltd. Pharmaceuticals: MajorHealth Technology Helmedix Pty Ltd. develops novel therapies for autoimmune diseases. It uses peptides derived from helminthes parasite to treat rheumatoid arthritis, colitis, psoriasis and multiple sclerosis. The company was founded by Andrew Hutchinson on December 1, 2012 and is headquartered in Melbourne, Australia. | Health Technology |
